Qilu Pharmaceutical presented the latest results of the single-arm, phase II pivotal clinical study for iparomlimab, an innovative Class 1 antibody monotherapy used to treat unresectable or metastatic dMMR/MSI-H solid tumors through a poster presentation at the European Society for Medical Oncology Asia Congress 2023 taken place from December 1-3.
Teva Pharmaceutical Industries Ltd. announces that a post hoc analysis4 of two phase 3 clinical studies presented at the European Headache Congress has shown the effectiveness of the migraine prevention treatment AJOVY® in reducing migraine attacks in patients with migraine and co-morbid obesity.
Sosei Group Corporation, notes its partner Neurocrine Biosciences Inc., a leading neuroscience-focused biopharmaceutical company, has confirmed its plans to evaluate two new muscarinic agonist candidates in Phase 1 first-in-human clinical studies.
Medivir AB, a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces that the company will present at the Carlsquare Equity Research Investor Day, December 6, 2023.
Medivir to present at the Carlsquare Equity Research Investor Day – December 06, 2023 Read More »
GC Biopharma, a South Korean biopharmaceutical company, announced on December 6th that it has participated in the groundbreaking ceremony of a plasma fractionation plant held at Jababeka Industrial Estate in Indonesia, one of the company’s overseas plant construction projects.
GC Biopharma’s groundbreaking for the plasma fractionation plant in Indonesia Read More »
Adcentrx Therapeutics, a biotechnology company dedicated to revolutionizing Antibody-Drug Conjugate therapeutics for cancer and other life-threatening diseases, announced the extension of its Series A+ financing.
Adcentrx Announces Extension of Series A+ Financing to $51 Million Read More »
EyePoint Pharmaceuticals, Inc. announced the pricing of an underwritten public offering of 11,764,706 shares of its common stock at a public offering price of $17.00 per share.
Arvinas, Inc. announced that a conference call and webcast will be held with executives from Arvinas and Pfizer Inc. to discuss vepdegestrant data presented at the 2023 San Antonio Breast Cancer Symposium as well as plans to expand the vepdegestrant development program.
The pharma industry serves patients best when data is shared, and privacy concerns can stand in the way of resolving critical supply chain issues.
Opinion: To Alleviate Supply Chain Shortages, Companies Should Share Data Read More »
Novartis today announced that the U.S. Food and Drug Administration (FDA) approved Fabhalta® (iptacopan) as the first oral monotherapy for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH)1.
